Statins increase risk of hemorrhagic stroke by inhibition of the PAR-1 receptor

Cerebrovascular Diseases

Volumn 24, Issue 5, 2007, Pages 477-479

  Serebruany, Victor L ^a,c   Malinin, Alex I ^a   Hennekens, Charles H ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Osler Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; CYCLOSPORIN; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CORONARY STENT; DEATH; GLOMERULOPATHY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; KIDNEY DISEASE; METABOLIC SYNDROME X; OSTEOLYSIS; PLEIOTROPY; PRIORITY JOURNAL; RISK; STROKE; THROMBOCYTE FUNCTION;

CEREBRAL HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTOR, PAR-1; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 35548978667     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108923     Document Type: Article

References (28)

1. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay J-F, Hennekens CH: Statins inhibit platelet PAR-1 thrombin receptor in patients with metabolic syndrome: the PAR-1 inhibition by statins (PARIS) study. Am J Cardiol 2006;97:1332-1336.
2. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR: Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-887.
3. Fenton JW Jr, Brezniak DV, Ofosu FA, Shen GX, Jacobson JR, Garcia JG: Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 2005;2:115-120.
4. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, Girgis RE, Garcia JG: Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 2004;30:662-670.
5. Fenton JW Jr, Shen GX: Statins as cellular antithrombotics. Haemostasis 1999;29:166-169.
6. Novela C, Hennekens CH: Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. J Cardiovasc Pharmacol Ther 2004;9:61-63.
7. Halcox JP, Deanfield JE: Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109(suppl 1):II42-II48.
8. Futterman LG, Lemberg L: Statin pleiotropy: fact or fiction? Am J Crit Care 2004;13:244-249.
9. Epstein M, Campese VM: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005;45:2-14.
10. McCarey DW, Sattar N, McInnes IB: Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 2005;7:55-61.
11. Sotiriou CG, Cheng JW: Beneficial effects of statins in coronary artery disease - beyond lowering cholesterol. Ann Pharmacother 2000;34:1432-1439.
12. Sanguigni V, Pignatelli P, Caccese D, Pulcinelli FM, Lenti L, Magnaterra R, Martini F, Lauro R, Violi F: Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost 2002;87:796-801.
13. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M: Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000;10:2442-2449.
14. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani A, Sturn DH, Patsch JR, Wiedermann CJ: CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin. Blood Coagul Fibrinolysis 2005;16:105-110.
15. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane D, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH: Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-2057.
16. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C: Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-1295.
17. Savi P, Pereillo JM, Uzabiaga MF: Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-896.
18. Williams D, Feely J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-370.
19. Hebert PR, Gaziano JM, Chan KS, Henneke. JAMA 1997;278:313-321.
20. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
21. SPARCL Investigators: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
22. Amarenco P, Tonkin AM: Statins for stroke prevention: disappointment and hope. Circulation 2004;109(23 suppl 1):III44-III49.
23. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, Colquhoun DM, Glasziou P, MacMahon S, Kirby AC, West MJ, Tonkin AM: Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-326.
24. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B: Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology 2007;68:737-742.
25. Nakaya N, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H;J-LIT Study Group: Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT). Circ J 2005;69:1016-1021.
26. Hennekens CH, Buring JE: Epidemiology in Medicine. Boston, Little, Brown and Company, 1987.
27. Serebruany VL, Oshrine BR, Malinin AI, Sane DC, Takserman A, Atar D, Hennekens CH: Lack of the uniformed platelet activation in patients after ischemic stroke. Thromb Res 2004;113:197-204.
28. Liu XS, Zhang ZG, Zhang L, Morris DC, Kapke A, Lu M, Chopp M: Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J Cereb Blood Flow Metab 2006;6:787-796.